Connor Clark & Lunn Investment Management Ltd. lowered its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 53.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 75,265 shares of the biopharmaceutical company's stock after selling 87,626 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 0.08% of Ultragenyx Pharmaceutical worth $4,181,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth approximately $1,323,000. Quest Partners LLC acquired a new stake in Ultragenyx Pharmaceutical in the third quarter worth approximately $119,000. Swiss National Bank boosted its stake in Ultragenyx Pharmaceutical by 9.1% during the 3rd quarter. Swiss National Bank now owns 159,152 shares of the biopharmaceutical company's stock valued at $8,841,000 after purchasing an additional 13,300 shares in the last quarter. Mutual of America Capital Management LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at $321,000. Finally, Natixis Advisors LLC raised its stake in shares of Ultragenyx Pharmaceutical by 290.0% in the 3rd quarter. Natixis Advisors LLC now owns 52,562 shares of the biopharmaceutical company's stock worth $2,920,000 after buying an additional 39,086 shares in the last quarter. Institutional investors own 97.67% of the company's stock.

Shares of Ultragenyx Pharmaceutical stock opened at $47.24 on Friday. The stock has a market cap of $4.36 billion, a PE ratio of -7.30 and a beta of 0.58. Ultragenyx Pharmaceutical Inc. has a 12 month low of $37.02 and a 12 month high of $60.37. The business has a fifty day simple moving average of $53.14 and a 200-day simple moving average of $48.39.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, beating the consensus estimate of ($1.45) by $0.05. The company had revenue of $139.49 million for the quarter, compared to analysts' expectations of $135.28 million. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The business's revenue for the quarter was up 42.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($2.23) EPS. Analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.21 EPS for the current fiscal year.

A number of research analysts recently issued reports on the company. HC Wainwright lifted their target price on Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the stock a "buy" rating in a report on Wednesday, November 6th. JPMorgan Chase & Co. lowered their price objective on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an "overweight" rating on the stock in a research note on Thursday. Cantor Fitzgerald reiterated an "overweight" rating and issued a $116.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. TD Cowen raised their target price on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a "buy" rating in a report on Monday, October 21st. Finally, Wells Fargo & Company upped their price target on Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the company an "overweight" rating in a report on Friday, August 2nd. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of "Moderate Buy" and a consensus target price of $87.46.

Read Our Latest Research Report on RARE

In related news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total value of $1,117,000.00. Following the completion of the sale, the chief executive officer now owns 2,223,985 shares of the company's stock, valued at approximately $124,209,562.25. The trade was a 0.89 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Howard Horn sold 7,465 shares of the stock in a transaction on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the transaction, the chief financial officer now directly owns 92,301 shares in the company, valued at $4,869,800.76. The trade was a 7.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 27,556 shares of company stock valued at $1,515,967. 5.80% of the stock is owned by insiders.

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Ultragenyx Pharmaceutical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultragenyx Pharmaceutical wasn't on the list.

While Ultragenyx Pharmaceutical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.